<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193881</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2010-01975</org_study_id>
    <secondary_id>NCI-2010-01975</secondary_id>
    <secondary_id>2009-0769</secondary_id>
    <secondary_id>8508</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>U01CA062461</secondary_id>
    <nct_id>NCT01193881</nct_id>
  </id_info>
  <brief_title>RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer</brief_title>
  <official_title>Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling
      pathway inhibitor RO4929097 (RO4929097) and erlotinib hydrochloride when given together in
      treating patients with non-small cell lung cancer that is stage IV or has come back.
      RO4929097 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of
      the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To define the maximum-tolerated dose (MTD) and toxicity of RO4929097 combined with
      erlotinib (erlotinib hydrochloride) in patients with advanced non-small cell lung cancer
      (NSCLC). (Dose escalation portion) II. To assess whether the probability of detectable tumor
      shrinkage or response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
      correlates with pre-therapy immunohistochemistry (IHC) and reverse phase protein array (RPPA)
      expression of Notch 1, 2, 3, and 4. (Dose escalation portion) III. A preliminary, exploratory
      assessment will be performed with respect to percent tumor shrinkage and the probability of
      response over the first 2 cycles of therapy. (Expansion cohort) IV. A preliminary,
      exploratory assessment will be performed with respect to change in tumor immunohistochemistry
      (IHC) scores and reverse phase protein array (RPPA) expression for Notch 1, 2, 3, and 4 over
      the first 2 cycles of erlotinib. (Expansion cohort)

      SECONDARY OBJECTIVES:

      I. To perform a preliminary exploratory assessment of whether probability of detectable tumor
      shrinkage/response correlates with pre RO4929097 presence in tumor of an activating epidermal
      growth factor receptor (EGFR) mutation, the T790M EGFR mutation, met proto-oncogene (c-MET)
      gene amplification or insulin-like growth factor 1 receptor (IGF-1R) expression or activation
      or various Notch pathway markers. (Dose escalation portion) II. To perform a preliminary
      exploratory assessment of whether addition of RO4929097 to erlotinib leads to tumor
      shrinkage/response in any tumor deposits that had previously exhibited growth on erlotinib
      alone. (Dose escalation portion) III. Conduct a preliminary exploratory assessment on the
      expansion cohort with respect to tumor shrinkage/response of the following over the first 2
      cycles of erlotinib and RO4929097 treatment with and without the presence of mutation,
      amplification, and activation of markers: tumor IHC scores and RPPA expression of the Notch
      ligand jagged 1 (Jag1), and the Notch targets hairy and enhancer of split 1 (HES1),
      hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1); tumor IHC scores and RPPA
      expression of putative stem cell markers cluster of differentiation (CD)24 (decreased in stem
      cells), CD44, CD133, dehydrogenase and of the epithelial to mesenchymal transition (EMT)
      markers E-cadherin and vimentin; detectability in tumor of EGFR T790M mutations, MET
      amplification, and IGF-1R expression and activation; and soluble markers of angiogenesis,
      including stromal cell-derived factor 1 alpha (SDF-1alpha), basic fibroblastic growth factor
      (bFGF), cryptic epitope of collagen IV, interleukin (IL)-6, IL-8, vascular endothelial growth
      factor (VEGF). (Expansion cohort) IV. Conduct a preliminary exploratory assessment of whether
      percent tumor shrinkage/response or time to progression correlates with pre-therapy IHC and
      RPPA expression of Notch 1, 2, 3 and 4, the above Notch pathway and stem cell markers, with
      baseline detectability of T790M mutations and MET amplification, and with baseline IGF-1R
      expression and activation, and with change in these markers from the initial biopsy to the
      subsequent biopsy. (Expansion cohort) V. In tumor samples collected both during the dose
      escalation phase and in the expansion cohort, assess if IHC and RPPA expression of Notch,
      Notch ligand and Notch targets correlates with expression of stem cell markers.

      VI. Assess if percent tumor shrinkage/response, time to progression and baseline and change
      in IHC and RPPA expression of Notch, Notch ligand, Notch targets and stem cell markers varies
      with: tumor Notch gene amplification as assessed by fluorescent in situ hybridization (FISH);
      tumor IHC and RPPA expression of selected members of the Wnt and Hedgehog pathways (since
      these could lead to stem cell properties in cells that do not express Notch); host
      (peripheral blood mononuclear cell) polymorphisms for relevant genes in the Notch pathway;
      tumor micro ribonucleic acid (RNA) levels.

      VII. Trough levels of erlotinib and RO4929097 will be measured in plasma samples of all
      patients on the dose-escalation portion of the study approximately 24 hours after the cycle
      1, day 1 dose and again approximately 24 hours after the cycle 2, day 1 dose. These
      measurements are being done to permit a preliminary exploratory assessment of whether there
      is induction of metabolism of one or both drugs that will lead to decreased drug plasma
      concentrations.

      VIII. In the Expansion Cohort, plasma levels of erlotinib and RO4929097 will be measured
      approximately 24 hours after the cycle 2, day 21 erlotinib dose (just prior to initiation of
      cycle 3), and plasma levels of both agents will be measured in plasma approximately 24 hours
      after the cycle 3, day 1 doses of both agents. These measurements are done to permit a
      preliminary exploratory assessment of whether: plasma drug levels correlate with % tumor
      shrinkage/response or with change in tumor biomarkers over the first 6 weeks of therapy;
      erlotinib plasma concentrations are affected by RO4929097 administration.

      OUTLINE: This is a dose-escalation study.

      Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-21 and
      gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and
      15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events assessed using NCI CTCAE version 4.0 (Dose escalation phase)</measure>
    <time_frame>Within 30 days of last drug dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose of RO4929097 and erlotinib hydrochloride defined as the highest dose tested causing dose limiting toxicity in &lt; 2/6 patients assessed using National Cancer Institute (NCI) CTCAE version 4.0 (Dose escalation phase)</measure>
    <time_frame>At least 3 weeks after day 1 of course 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of change in expression of Notch and other tumor and blood biomarkers (Expansion cohort)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The differences before and after treatment will be assessed using a paired-t test on the log-transformed tumor sizes and a Wilcoxon signed-rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of tumor shrinkage (Expansion cohort)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Will be correlated with response and baseline expression of biomarkers. The differences before and after treatment will be assessed using a paired-t test on the log-transformed tumor sizes and a Wilcoxon signed-rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate by RECIST 1.1 (Expansion cohort)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression (Expansion cohort)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Will be correlated with baseline expression or biomarkers.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Efficacy of this combination in unselected patients and in patients with intrinsic or acquired erlotinib resistance (Dose escalation phase)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Host Notch pathway gene polymorphisms</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Correlations between Notch pathway gene polymorphisms and tumor and blood biomarkers will be assessed. Correlations between Notch pathway gene polymorphisms and tumor shrinkage/response on therapy will also be assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pre-therapy tumor expression of Notch and other tumor and blood biomarkers (Dose escalation phase)</measure>
    <time_frame>Baseline</time_frame>
    <description>Exploratory assessments of correlations of tumor shrinkage and response on the combination with pre-therapy tumor expression of Notch and other tumor and blood biomarkers will be conducted.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stem cell markers</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Correlations between Notch pathway markers and stem cell markers will be assessed.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Recurrent Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IV Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
    <other_name>Cp-358,774</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma-Secretase Inhibitor RO4929097</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
    <other_name>RO4929097</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dose-escalation portion:

               -  Patients must have histologically or cytologically confirmed diagnosis of
                  incurable NSCLC

               -  Preference will be given to patients with NSCLC who have been treated with
                  erlotinib, and have either responded initially and then experienced subsequent
                  growth in one or more tumor deposits while continuing erlotinib (acquired
                  resistance) or patients who have been treated with erlotinib and failed to
                  demonstrate any response to it (intrinsic resistance)

          -  Expansion cohort: patients must satisfy each of the following criteria:

               -  Histologically or cytologically confirmed non-small cell lung cancer that is
                  incurable (stage IV or recurrent)

               -  Patients must not have received prior anti-EGFR therapy

          -  Patients on both the dose escalation portion of the study and in the Expansion Cohort
             portion must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             10 mm with computed tomography (CT) scan with cuts at 2.5 or 5 mm

          -  Patients on both portions of the study must have tumor amenable to core biopsy (or to
             incisional, excisional, or punch biopsy) for research purposes; the collaborating
             interventional radiologists will make the determination whether or not the patient has
             a tumor amenable to biopsy and whether or not the patient is medically an appropriate
             candidate for tumor biopsy

          -  Any prior anticancer systemic therapy or radiotherapy must have been completed at
             least 4 weeks prior to initiation of therapy on this study; (Exception: patients may
             be entered within 2 weeks of radiotherapy if the radiotherapy was restricted to femur
             below the trochanter, humerus or more distal limb areas)

          -  Dose escalation portion:

               -  Unlimited prior therapy is permitted (including prior anti-EGFR therapy), with
                  the exception that patients who have received prior therapy with a
                  gamma-secretase inhibitor are not eligible

               -  Prior therapy is not required

               -  Preference will be given to NSCLC patients who have been treated with erlotinib
                  with evidence of acquired or intrinsic resistance to erlotinib

          -  Expansion cohort:

               -  Patients may have received an unlimited number of prior systemic regimens for
                  NSCLC (as adjuvant therapy, as therapy for locally advanced disease or as therapy
                  for advanced disease) provided they have not received prior anti-EGFR therapy
                  (small molecule or antibody, etc) or prior gamma-secretase inhibitors

               -  Prior therapy is not required

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 60%)

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets&gt;= 100,000/mcL

          -  Hemoglobin &gt;= 9 g/dL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 X
             institutional upper limit of normal

          -  Creatinine =&lt; 1.5 X institutional upper limit of normal

          -  International normalized ratio (INR) =&lt; 1.7 X upper limit of normal (ULN) and the
             patient must not have received aspirin or Coumadin and the patient must not have
             received aspirin or Coumadin within the previous week or a therapeutic dose of a
             heparin product within the previous 24 hours

          -  Women of childbearing potential must use two forms of contraception (i.e., barrier
             contraception and one other method of contraception) from at least 2 weeks prior to
             initiation of therapy on this study, for the duration of study participation, and for
             at least 2 months post-treatment; should a woman become pregnant or suspect she is
             pregnant while she or her partner are participating in this study and for 2 months
             after study participation, the patient should inform the treating physician
             immediately

               -  Women of childbearing potential are required to have a negative serum pregnancy
                  test (with a sensitivity of at least 25 mIU/mL) within 14 days prior to the first
                  dose of RO4929097 and a negative serum or urine pregnancy test within 24 hours
                  prior to the first dose of RO4929097; following initiation of therapy with
                  RO4929097, a pregnancy test (serum or urine) will be administered every 3 weeks
                  while on study; a positive urine test must be confirmed by a serum pregnancy
                  test; prior to dispensing RO4929097, the investigator or designate must confirm
                  and document the patient's use of two contraceptive methods, dates of negative
                  pregnancy test, and confirm the patient's understanding of the teratogenic
                  potential of RO4929097

               -  Patients with a positive pregnancy test who are unlikely to be pregnant may be
                  considered for entry on this trial if they are deemed to be unlikely to be
                  pregnant by an obstetrician or gynecologist and if the study sponsor is in
                  agreement with their study entry

               -  Female patients of childbearing potential are defined as patients who do not fall
                  into either of the categories listed above and to whom any of the following
                  apply:

                    -  Patients with regular menses

                    -  Patients, after menarche with amenorrhea, irregular cycles, or using a
                       contraceptive method that precludes withdrawal bleeding

                    -  Women who have had tubal ligation

               -  Female patients may be considered to NOT be of childbearing potential for the
                  following reasons:

                    -  The patient has undergone total abdominal hysterectomy with bilateral
                       salpingo-oophorectomy or bilateral oophorectomy

                    -  The patient is medically confirmed to be menopausal (no menstrual period)
                       for 24 consecutive months

          -  Men participating in the study must also use 2 methods of contraception including 1
             barrier method

          -  Breastfeeding should be discontinued if the mother is treated with RO4929097

          -  Patients with asymptomatic or minimally symptomatic brain metastases will not be
             required to undergo cranial radiation prior to being considered for this trial, and
             are eligible provided that it is not anticipated that they will require any of the
             following over the course of study treatment:

               -  Corticosteroids for control of cerebral edema

               -  Enzyme-inducing anticonvulsants

               -  Radiotherapy, surgery, or other local therapy for the brain metastases

          -  Able to swallow oral medications

        Exclusion Criteria:

          -  Patients may not have received other systemic therapy or radiotherapy for their cancer
             within the previous 4 weeks prior to planned first day of therapy on this trial;
             (Exception: patients may be entered within 2 weeks of radiotherapy if the radiotherapy
             was restricted to distal limbs such as femur below the trochanter, humerus or more
             distal limb areas; in addition, patients in the dose escalation portion who have
             previously received erlotinib may start therapy on this trial as early as 1 week after
             stopping prior erlotinib provided all other study entry criteria are met)

          -  Patients on the expansion cohort may not have received prior anti-EGFR therapy (small
             molecule tyrosine kinase inhibitor [TKI] or antibody); (Note: this in contrast to the
             dose escalation portion of the study in which patients with prior anti-EGFR therapy
             will be eligible)

          -  Patients may not be receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to RO4929097, OSI-774 or other agents used in the study

          -  Patients taking medications with narrow therapeutic indices that are metabolized by
             cytochrome P450 (CYP450), including warfarin sodium (CoumadinÂ®) are ineligible

          -  Caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates,
             inducers, and/or inhibitors; furthermore, patients who are taking concurrent
             medications (other than erlotinib) that are strong inducers/inhibitors or substrates
             of CYP3A4 should be switched to alternative medications; if such patients cannot be
             switched to alternative medications, they will be ineligible to participate in this
             study; if a patient is taking a strong CYP3A4 inhibitor/inducer other than the 2 study
             drugs, they should be switched to an alternative drug

          -  Patients with malabsorption syndrome or other condition that would interfere with
             intestinal absorption

          -  Diarrhea &gt; grade 1 despite appropriate therapy

          -  Patients who are known to be serologically positive for hepatitis A, B or C are
             ineligible

          -  Patients with &gt; grade 1 (by Common Terminology Criteria for Adverse Events [CTCAE]
             criteria) hyponatremia or hypocalcemia (based on measurement of ionized calcium)
             despite appropriate medical management are excluded from this study, as are patients
             with hypophosphatemia (serum phosphate below the lower limit of normal for the
             institution), hypomagnesemia, (serum magnesium below the lower limit of normal),
             hypokalemia, or hyperkalemia (serum potassium outside normal limits) despite
             appropriate medical management

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring systemic therapy (with antibiotics, antiviral or antifungal
             agents), symptomatic congestive heart failure, unstable angina pectoris, angina at
             rest, a history of torsades de pointes, potentially life-threatening cardiac
             arrhythmias (patients are permitted to have chronic, stable atrial fibrillation,
             premature atrial or ventricular contractions, sinus tachycardia, provided the rate is
             controlled at &lt; 115 per minute, and sinus bradycardia, provided the rate is &gt; 50 per
             minute), myocardial infarction within the previous 3 months, or psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Pregnant women are excluded from this study

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Cardiovascular: baseline corrected QT interval using Fridericia's formula (QTcF) &gt; 450
             msec (male) or QTcF &gt; 470 msec (female)

          -  Patients requiring drugs that are known to cause Torsades de pointes and/or prolonged
             corrected QT (QTc) intervals are excluded; patients requiring drugs with a possible
             but unproven association with Torsades de pointes and/or QTc prolongation may be
             eligible, but will require additional electrocardiogram assessments, as outlined

          -  Patients who have not recovered to &lt; CTCAE grade 2 toxicities related to prior therapy
             are not eligible to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Gibbons</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

